Medically Reviewed by Dr. Rafael Morales, PharmD, BCACP, CDE
Clinical Pharmacist — Diabetes & Metabolic Disease
Last reviewed: March 30, 2026
Tirzepatide is a once-weekly injectable prescription medication that activates both the GIP and GLP-1 hormone receptors — making it the first dual GIP/GLP-1 receptor agonist approved by the FDA. It is sold as Mounjaro for type 2 diabetes and as Zepbound for chronic weight management and obstructive sleep apnea.
Typical Cost
$299–$1,112/month
Forms
subcutaneous injection (autoinjector pen) +2
Status
Rx
Generic
Brand Only
Exenatide is the lowest-cost GLP-1 Receptor Agonists at $600–$1,000/month/month
Uses & Indications
Mounjaro (tirzepatide) is FDA-approved as an adjunct to diet and exercise to improve glycemic control in:
- Adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus
Zepbound (tirzepatide) is FDA-approved for:
- Chronic weight management in adults with initial BMI ≥30 kg/m² (obesity), or ≥27 kg/m² (overweight) with at least one weight-related comorbidity (hypertension, dyslipidemia, type 2 diabetes, obstructive sleep apnea, or cardiovascular disease), used as an adjunct to a reduced-calorie diet and increased physical activity
- Moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity
Off-label uses (not FDA-approved but clinically practiced):
- Mounjaro prescribed for weight loss in patients without type 2 diabetes
- Non-alcoholic steatohepatitis (NASH) — under clinical investigation
Tirzepatide is not approved for type 1 diabetes or diabetic ketoacidosis.
Mounjaro vs. Zepbound — What's the Difference?
Both Mounjaro and Zepbound contain tirzepatide at identical doses, but they carry different FDA indications, list prices, and insurance coverage rules.
Mounjaro
FDA-approved for type 2 diabetes
~$1,086–$1,112/month list price
Zepbound
FDA-approved for weight loss & sleep apnea
Vials from $299/month via LillyDirect
Active Ingredient
Identical — tirzepatide at the same doses
2.5 mg → 15 mg once weekly
Dosage & Administration
Starting dose: 2.5 mg subcutaneously once weekly for 4 weeks (initiation dose only — not intended for glycemic control).
Titration schedule (increase every 4 weeks as tolerated):
| Week | Dose |
|---|---|
| Weeks 1–4 | 2.5 mg once weekly |
| Weeks 5–8 | 5 mg once weekly |
| Weeks 9–12 (optional) | 7.5 mg once weekly |
| Weeks 13–16 (optional) | 10 mg once weekly |
| Weeks 17–20 (optional) | 12.5 mg once weekly |
| Week 21+ (optional) | 15 mg once weekly |
Maximum doses:
- Adults (Mounjaro/Zepbound): 15 mg once weekly
- Pediatric patients aged 10+ (Mounjaro only): 10 mg once weekly
Administration:
- Inject subcutaneously in the abdomen, thigh, or upper arm (caregiver-administered only for upper arm)
- Rotate injection sites with each dose
- Administer on the same day each week, at any time of day, with or without food
- If a dose is missed: administer as soon as possible within 4 days (96 hours). If more than 4 days have passed, skip the missed dose and resume the regular schedule
- The day of weekly administration can be changed as long as at least 3 days (72 hours) separate consecutive doses
- When used with insulin: administer as separate injections; do not mix. Injections may be in the same body region but not adjacent
Available formulations:
- Mounjaro: Single-dose autoinjector pen (2.5, 5, 7.5, 10, 12.5, 15 mg); single-dose vials; KwikPen multi-dose pen
- Zepbound: Single-dose autoinjector pen (2.5, 5, 7.5, 10, 12.5, 15 mg); single-dose vials (2.5 mg, 5 mg — lower list price via LillyDirect)
Storage: Refrigerate at 36°F–46°F (2°C–8°C). May be stored at room temperature (up to 86°F/30°C) for up to 21 days. Do not freeze. Protect from light.
How It Works
Tirzepatide is a dual GIP/GLP-1 receptor agonist — the first in its class. It is a 39-amino acid synthetic peptide with a C20 fatty diacid moiety attached via a linker, which enables albumin binding and extends the plasma half-life to approximately 5 days, supporting once-weekly dosing.
GLP-1 receptor activation produces:
- Glucose-dependent stimulation of insulin secretion (first and second phase)
- Suppression of glucagon secretion in a glucose-dependent manner
- Slowing of gastric emptying, which reduces post-meal glucose spikes
- Reduction of appetite and food intake via central nervous system pathways
GIP receptor activation adds:
- Enhanced insulin secretion (complementary to GLP-1 pathway)
- Improved insulin sensitivity in adipose tissue
- Possible amplification of the weight-loss effects of GLP-1 signaling
- Reduction of glucagon secretion at supraphysiological doses
The dual mechanism explains why tirzepatide consistently outperforms GLP-1-only agents in head-to-head trials. In SURMOUNT-5 (NEJM, 2025), tirzepatide produced 20.2% weight loss versus 13.7% with semaglutide 2.4 mg at 72 weeks — a statistically significant 6.5 percentage point difference.
Unlike insulin, tirzepatide's effects on insulin secretion and glucagon suppression are glucose-dependent, meaning the risk of hypoglycemia when used as monotherapy is very low.
Side Effects
Serious Side Effects
Common Side Effects
Rare Side Effects
Warnings & Precautions
BLACK BOX WARNING — Thyroid C-Cell Tumors Tirzepatide caused dose-dependent and treatment-duration-dependent thyroid C-cell tumors (adenomas and carcinomas) in both sexes of rats and mice at clinically relevant exposures. It is unknown whether tirzepatide causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans. Tirzepatide is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Counsel patients regarding the potential risk of MTC and the symptoms of thyroid tumors (neck mass, dysphagia, dyspnea, persistent hoarseness). Routine serum calcitonin monitoring or thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with tirzepatide.
Acute Pancreatitis Acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, has been reported. Discontinue tirzepatide promptly if pancreatitis is suspected. Do not restart if pancreatitis is confirmed. Consider other antidiabetic therapies in patients with a history of pancreatitis.
Hypoglycemia with Insulin Secretagogues or Insulin The risk of hypoglycemia is increased when tirzepatide is used in combination with insulin secretagogues (e.g., sulfonylureas) or insulin. Consider reducing the dose of the secretagogue or insulin to reduce the risk of hypoglycemia.
Acute Kidney Injury Tirzepatide can cause acute kidney injury, typically as a consequence of dehydration from nausea, vomiting, and diarrhea. Monitor renal function in patients experiencing severe GI adverse reactions and in patients with renal impairment.
Severe Gastrointestinal Adverse Reactions Severe GI adverse reactions, including nausea, vomiting, and diarrhea, have been reported. These reactions can lead to dehydration and acute kidney injury. Dose escalation should be gradual to reduce GI risk. Consider dose reduction or discontinuation in patients with persistent severe GI symptoms.
Diabetic Retinopathy Complications Rapid improvement in glycemic control has been associated with temporary worsening of diabetic retinopathy. Monitor patients with a history of diabetic retinopathy.
Acute Gallbladder Disease Cholelithiasis and cholecystitis have been reported. If cholelithiasis is suspected, gallbladder studies and appropriate clinical follow-up are indicated.
Pulmonary Aspiration Cases of pulmonary aspiration during general anesthesia or deep sedation have been reported in patients on GLP-1 receptor agonists. Consider withholding tirzepatide for a sufficient time before elective procedures requiring anesthesia.
Contraindications
Tirzepatide is contraindicated in patients with:
- Personal or family history of medullary thyroid carcinoma (MTC) — due to the risk of thyroid C-cell tumors observed in animal studies
- Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) — same rationale as above
- Known serious hypersensitivity to tirzepatide or any component of the product — reactions including anaphylaxis and angioedema have been reported
Tirzepatide is not approved for type 1 diabetes mellitus or diabetic ketoacidosis.
Drug Interactions
Tirzepatide does not inhibit or induce cytochrome P450 enzymes and is not a substrate of CYP enzymes, so direct pharmacokinetic drug interactions via CYP pathways are not expected.
Clinically significant interactions:
Insulin and insulin secretagogues (sulfonylureas, meglitinides): Concomitant use increases the risk of hypoglycemia. Consider reducing the dose of insulin or the secretagogue when initiating tirzepatide. Monitor blood glucose closely.
Oral medications with narrow therapeutic index: Tirzepatide slows gastric emptying, which can affect the rate (but not the extent) of absorption of orally administered drugs. Use caution with drugs that require rapid GI absorption (e.g., some antibiotics, oral contraceptives). For oral contraceptives, consider using a non-oral contraceptive method or adding a barrier method for 4 weeks after initiating tirzepatide and for 4 weeks after each dose escalation.
Warfarin (and other oral anticoagulants): Slowed gastric emptying may alter warfarin absorption. Monitor INR closely when initiating or adjusting tirzepatide dose.
No significant interactions expected with: metformin, DPP-4 inhibitors, SGLT-2 inhibitors, statins, ACE inhibitors, ARBs, beta-blockers, or most other commonly co-prescribed medications.
Use in Specific Populations
Pregnancy: Tirzepatide is not recommended during pregnancy. Discontinue at least 2 months before a planned pregnancy. Adverse effects on fetal development were observed in animal studies. There are no adequate and well-controlled studies in pregnant women. If a patient becomes pregnant while taking tirzepatide, discontinue and notify the prescriber.
Lactation: It is not known whether tirzepatide is excreted in human breast milk. Because of the potential for serious adverse reactions in nursing infants, advise patients not to breastfeed during treatment with tirzepatide.
Pediatric patients: Mounjaro is approved for pediatric patients aged 10 years and older with type 2 diabetes. The maximum dose in pediatric patients is 10 mg once weekly. Zepbound is not approved for pediatric use.
Geriatric patients (≥65 years): No dose adjustment is required. Clinical trials included patients up to 85 years of age. Older patients may be more susceptible to dehydration from GI adverse reactions; monitor renal function.
Renal impairment: No dose adjustment required for any degree of renal impairment. Use with caution in end-stage renal disease; monitor for dehydration-related acute kidney injury.
Hepatic impairment: No dose adjustment required for mild, moderate, or severe hepatic impairment.
Overdosage
In the event of overdose, initiate appropriate supportive treatment according to the patient's clinical signs and symptoms. Prolonged observation may be necessary given the approximately 5-day half-life of tirzepatide. Symptomatic management of nausea, vomiting, and hypoglycemia (if co-administered with insulin or secretagogues) is the primary approach. There is no specific antidote for tirzepatide overdose.
Frequently Asked Questions
What is tirzepatide used for?
Tirzepatide is used for two main conditions: (1) type 2 diabetes — sold as Mounjaro, approved May 2022; and (2) chronic weight management and obstructive sleep apnea — sold as Zepbound, approved November 2023. Both brands contain the same active ingredient at the same doses.
How is tirzepatide different from semaglutide (Ozempic, Wegovy)?
Semaglutide activates only the GLP-1 receptor. Tirzepatide activates both the GLP-1 and GIP receptors simultaneously — a dual mechanism that produces stronger blood sugar control and greater weight loss. In the SURMOUNT-5 trial, tirzepatide produced 20.2% weight loss versus 13.7% with semaglutide 2.4 mg at 72 weeks.
How do you inject tirzepatide?
Tirzepatide is injected subcutaneously (under the skin) once weekly in the abdomen, thigh, or upper arm. It can be given at any time of day, with or without food. Rotate injection sites with each dose to reduce injection site reactions.
What are the most common side effects of tirzepatide?
The most common side effects are gastrointestinal: nausea (12–22%), diarrhea (12–16%), vomiting (6–13%), constipation (6–9%), and abdominal pain (8–11%). These are most pronounced during dose escalation and typically improve after the first 4–8 weeks. Starting at the lowest dose (2.5 mg) and titrating slowly reduces GI side effects.
Can tirzepatide cause low blood sugar (hypoglycemia)?
Tirzepatide alone has a low risk of hypoglycemia because its insulin-stimulating effects are glucose-dependent — it only stimulates insulin when blood sugar is elevated. However, the risk increases significantly when tirzepatide is combined with insulin or sulfonylureas (e.g., glipizide, glimepiride). If you take these medications together, your doctor may reduce the dose of insulin or the sulfonylurea.
Is tirzepatide safe during pregnancy?
No. Tirzepatide is not recommended during pregnancy. Animal studies showed adverse effects on fetal development. Discontinue tirzepatide at least 2 months before a planned pregnancy, as it takes approximately 5 half-lives (about 5 weeks) to clear from the body. If you become pregnant while taking tirzepatide, stop immediately and contact your healthcare provider.
How much does tirzepatide cost without insurance?
Without insurance, Mounjaro and Zepbound autoinjector pens list at approximately $1,086–$1,112 per month. Zepbound single-dose vials available through LillyDirect cost $299–$549/month depending on dose — the most affordable option for uninsured patients. Eli Lilly's savings card reduces cost to as low as $25/month for commercially insured patients.
What is the maximum dose of tirzepatide?
The maximum dose for adults is 15 mg once weekly. For pediatric patients aged 10 and older (Mounjaro only), the maximum dose is 10 mg once weekly. Treatment starts at 2.5 mg and is increased by 2.5 mg every 4 weeks as tolerated.
Protect your muscle mass while taking tirzepatide (Mounjaro)
GLP-1 medications can cause up to 39% muscle loss alongside fat. Zova's AI-powered protocol — backed by Lancet Diabetes & Endocrinology research — reduces that to just 8.7% through leucine tracking and injection-day adaptive nutrition.
No credit card. No commitment.
Medical Disclaimer
The information on RxGuide is intended for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician, pharmacist, or other qualified health provider with any questions you may have regarding a medical condition or medication. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.